Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...
Schizophrenia is a common psychiatric disorder involving approximately 1% of the population worldwide. Family, twin, and adoption studies suggest genetic factors contribute to this illness (Lang et al ...
Purpose: To develop a high resolution microarray based method to detect single- and multiexons gene deletions and duplications. Methods: We have developed a high-resolution comparative genomic ...
Agilent Technologies Inc. has introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer ...
The array technology can accommodate a starting genomic DNA samples as small as 25 ng, and Agilent’s CGH Analytics software allows for simultaneous analysis, visualization, and comparison of multiple ...
Roche NimbleGen, Inc. has launched NimbleGen Comparative Genomic Hybridization (CGH) microarrays in a 12x135K format for analysis of DNA copy number variation. NimbleGen CGH 12x135K arrays will allow ...
PALO ALTO, Calif., Jan. 5, 2005 -- Agilent Technologies Inc. (NYSE: A) today announced a breakthrough development that enables the rapid advance of microarray-based comparative genomic studies in ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.
Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma Genomic losses were ...
Bioinformatics-analysis division is a division of CD Genomics, which provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, ...
Births in Italy and Germany from eggs tested by CGH Two women taking part in the world's first controlled study of a comprehensive genetic screening test before IVF have given birth to healthy babies.
MADISON, Wis.--(BUSINESS WIRE)-- Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announced today that Seoul-based genomic services provider Macrogen, Inc. has officially joined the Roche NimbleGen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback